Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer [Gynecologic Cancer]

Conclusion This study, to our knowledge, is the first to explore the effects of nivolumab against ovarian cancer. The encouraging safety and clinical efficacy of nivolumab in patients with platinum-resistant ovarian cancer indicate the merit of additional large-scale investigations (UMIN Clinical Trials Registry UMIN000005714).

http://jco.ascopubs.org/cgi/content/short/33/34/4015?rss=1

Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Hamanishi, Mandai, Ikeda, Minami, Kawaguchi, Murayama, Kanai, Mori, Matsumoto, Chikuma, Matsumura, Abiko, Baba, Yamaguchi, Ueda, Hosoe, Morita, Yokode, Shimizu, Honjo, Konishi Tags: Translational Oncology, Gynecologic Gynecologic Cancer Source Type: research